St. Vincent’s Hospital The Catholic University of Korea | South Korea
PUBLICATION PROFILE
👩‍⚕️ INTRODUCTION
Prof. JeongA Kim, a distinguished physician-scientist in the field of Hematology and Oncology, hails from the Republic of Korea. Holding Medical License No. 42831, she currently serves as a Professor of Internal Medicine at St. Vincent’s Hospital, The Catholic University of Korea, located in Suwon-si, Gyeonggi-do. With decades of academic, clinical, and research experience, Prof. Kim is a well-respected figure in both Korean and international hematology communities. Her dedication to clinical excellence and scientific research in malignant hematologic diseases, stem cell transplantation, and lymphomas has significantly influenced patient care standards and academic development in hematology.
🎓 EARLY ACADEMIC PURSUITS
Prof. Kim’s medical journey began at Catholic University Medical College, where she completed her premedical and medical studies from 1984 to 1990, earning her MD. She later advanced academically by pursuing a Master’s degree (1996–1998) and a Ph.D. (1998–2001) from The Catholic University of Korea, Graduate School. Her academic excellence and passion for medicine laid a solid foundation for her remarkable professional career.
🏥 PROFESSIONAL ENDEAVORS
Her professional training started with an internship at St. Mary’s Hospital (1990–1991) and a residency in Internal Medicine (1991–1995). She then undertook a fellowship in Hemato-Oncology at Samsung Medical Center (1995–1997). From 1997 onwards, she has been an integral part of St. Vincent Hospital, where she currently serves as the Chief of Hematology and Stem Cell Transplantation Center since 2018. Prof. Kim has ascended the academic ladder from Instructor to full Professor, reflecting her dedication to medical education, mentorship, and research.
🧬 CONTRIBUTIONS AND RESEARCH FOCUS
With a robust background in hematologic malignancies, stem cell transplantation, and clinical trial research, Prof. Kim has participated in over 60 national and international clinical trials. Her research has explored new therapeutic strategies in multiple myeloma, CML, lymphomas, and acute leukemias, among others. Her work includes pivotal studies like MANIFEST-2, Olympia series, and DRAMA, along with surveillance and real-world evidence studies on novel agents such as Carfilzomib, Radotinib, and Dasatinib. She has also shown profound interest in geriatric oncology, epigenetic priming, and precision medicine through biomarker-based research.
🌍 IMPACT AND INFLUENCE
Prof. Kim is a member of key professional societies, including the Korean Association of Internal Medicine, Korean Hematology Association, Korean Stem Cell Transplantation Association, and the prestigious American Hematology Association. Her work has had a substantial impact on treatment guidelines, clinical protocols, and training of new physicians in Korea and abroad. As an educator, she has mentored countless medical students, residents, and fellows over her decades-long academic career.
đź“š ACADEMIC CITATIONS AND PUBLICATIONS
Prof. Kim’s contributions to the field have been widely disseminated through peer-reviewed journals, clinical trial presentations, and medical symposiums. Although specific citation metrics are not included here, her extensive clinical trial involvement and continuous publication of findings highlight her academic productivity. Her work is frequently referenced in hematology research both in Korea and internationally.
🏅 HONORS & AWARDS
While detailed award listings are not provided, Prof. Kim’s elevation to full professorship, appointment as department chief, and active role in clinical trials are clear indicators of her recognition and trust within the medical community. Her continuous GCP (Good Clinical Practice) certifications, spanning over a decade, underscore her ethical integrity, research compliance, and commitment to quality in clinical research.
🔬 LEGACY AND FUTURE CONTRIBUTIONS
Prof. JeongA Kim’s legacy lies in her lifelong dedication to hematologic research, patient care, and academic leadership. Her ongoing work with next-generation therapeutics, epigenetic therapies, and novel bispecific antibodies signifies her focus on shaping the future of precision hematology. As she continues to collaborate in global clinical trials and lead advanced stem cell transplantation programs, Prof. Kim stands as a guiding figure for the next generation of hematologists.
đź“ť FINAL NOTE
Prof. JeongA Kim exemplifies what it means to be a clinician-scientist, educator, and leader. Her journey from student to professor and department chief is a testament to her perseverance, excellence, and visionary impact on the field of hematology. Her unwavering commitment to advancing clinical care, medical education, and innovative research continues to uplift patient outcomes and inspire medical professionals globally.
 📚 TOP NOTES PUBLICATIONS
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
-
Authors: Nancy L. Bartlett, Uwe H. Hahn, Won-Seog Kim, Fei Jie, Jeong-ah Kim
-
Journal: Journal of Clinical Oncology
-
Year: 2025
The Presence of Clonal Isotype Switch After Autologous Stem Cell Transplantation as a Prognostic Biomarker for Long-Term Survival in Patients with Multiple Myeloma
-
Authors: Hanwool Cho, Jinhang Kim, Youngrok Park, Yeongsic Kim, Jeong-ah Kim
-
Journal: Leukemia Research
-
Year: 2025
 Early Dose Reduction of Dasatinib Does Not Compromise Clinical Outcomes in Patients with Chronic Myeloid Leukemia: A Comparative Analysis of Two Prospective Trials
-
Authors: Dong-yeop Shin, Sahee Park, Eunjung Jang, Won-sik Lee, Dong-wook Kim
-
Journal: Leukemia Research
-
Year: 2024
Geriatric Risk Model for Older Patients with Diffuse Large B-Cell Lymphoma (GERIAD): A Prospective Multicenter Cohort Study
-
Authors: Ho Young Yhim, Yong Park, Jeong-ah Kim, Deok-hwan Yang, Jae-yong Kwak
-
Journal: Taehan Naekwa Hakhoe chapchi = The Korean Journal of Internal Medicine
-
Year: 2024